Treatable Causes of Peripheral Neuropathy
Always screen for and treat the following reversible causes of peripheral neuropathy: vitamin B12 deficiency, hypothyroidism, diabetes mellitus, alcohol toxicity, neurotoxic medications, renal disease, monoclonal gammopathies, infections (particularly HIV), and chronic inflammatory demyelinating neuropathy. 1, 2
Primary Treatable Causes to Evaluate
The most recent diabetes care guidelines 2, 3 and comprehensive reviews 4 emphasize that peripheral neuropathy is a diagnosis of exclusion—you must actively rule out treatable causes before attributing symptoms to idiopathic or irreversible disease.
Metabolic and Endocrine Causes
Diabetes mellitus: The most common cause globally, affecting approximately 206 million people. Tight glycemic control (HbA1c 6-7%) can prevent or delay progression in type 1 diabetes and modestly slow progression in type 2 diabetes 5, 1, 3
Hypothyroidism: Routinely screen with thyroid-stimulating hormone levels 1, 6
Vitamin B12 deficiency: Check serum B12 with metabolites (methylmalonic acid ± homocysteine) as part of initial workup. Correction of deficiency can halt progression 1, 4, 6
Toxic Causes
Hematologic and Immunologic Causes
Monoclonal gammopathies: Screen with serum protein electrophoresis with immunofixation. Multiple myeloma and other paraproteinemias are treatable 1, 4, 6
Chronic inflammatory demyelinating neuropathy (CIDP): Responds to immunotherapy, often intravenous immunoglobulin 1, 7
Vasculitis: May require immunosuppressive therapy 1
Infectious Causes
- HIV infection: Screen in appropriate clinical contexts 1
Renal Disease
- Uremia: Metabolic toxicants from renal insufficiency damage nerves; dialysis or transplantation may help 5, 1
Initial Laboratory Evaluation Algorithm
Order these tests first for every patient with peripheral neuropathy 1, 4, 6:
- Complete blood count
- Comprehensive metabolic profile (includes renal function)
- Fasting blood glucose or HbA1c
- Vitamin B12 with metabolites (methylmalonic acid ± homocysteine)
- Thyroid-stimulating hormone
- Serum protein electrophoresis with immunofixation
- Erythrocyte sedimentation rate
Order specialized tests only if clinically indicated based on history, examination findings, or initial test abnormalities 1, 6:
- HIV testing
- Hepatitis serologies
- Specific antibody assays
- Lumbar puncture (for Guillain-Barré syndrome or CIDP)
- Electrodiagnostic studies (if diagnosis unclear or atypical features)
Critical Clinical Pitfalls
Do not assume diabetic neuropathy in a diabetic patient without excluding other causes. The guidelines explicitly state that diabetic neuropathy is a diagnosis of exclusion, and nondiabetic neuropathies may be present and treatable even in patients with diabetes 1.
Do not overlook medication-induced neuropathy. Carefully review all medications, including chemotherapy agents, and consider discontinuation or dose reduction of offending agents 1, 4.
Do not miss B12 deficiency. Standard serum B12 levels can be falsely normal; always check metabolites (methylmalonic acid) for definitive diagnosis 1, 4, 6.
Treatment Priorities
While treating the underlying cause is paramount, recognize that complete reversal of nerve damage is uncommon even with treatment 4. However, early intervention can:
- Halt progression
- Prevent further neuronal loss
- Reduce morbidity and disability 8
For diabetic neuropathy specifically, glycemic control prevents development in type 1 diabetes and slows progression in type 2 diabetes, but does not reverse established neuronal loss 2, 3. Managing other cardiovascular risk factors (lipids, blood pressure) may also slow DPN progression 3.
The key to improving outcomes is early pattern recognition, systematic evaluation for treatable causes, and prompt intervention before irreversible nerve damage occurs 8, 9.